Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV (NCT06624839)
A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).
Who can join: Review the eligibility criteria below.
Location: RIIS Clinic at HIPS — Washington D.C., District of Columbia
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- RIIS Clinic at HIPS — Washington D.C., District of Columbia
- RIIS Clinic at Baltimore Safe Haven — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 706-1372
Email: oharfouch@ihv.umaryland.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Human Papilloma Virus
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers — Chicago, Illinois
- Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study — Albany, Georgia
- Impact of Standing Orders Optimization — Chapel Hill, North Carolina
- Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old — Boston, Massachusetts
- Impact of Financial Incentives — Chapel Hill, North Carolina
- Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test — San Salvador,
Explore by condition: All Human Papilloma Virus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.